Dr. Reddy's Approves Re-appointment of Director, Appoints New Director & Auditor at AGM
Dr. Reddy's AGM on July 23, 2026, saw members approve Dr. K P Krishnan's re-appointment as Independent Director (Jan 7, 2027 - Jan 6, 2032) and Mr. Srikanth Velamakanni's appointment (Jul 1, 2026 - Jun 30, 2031). Deloitte Haskins & Sells, LLP appointed as Statutory Auditors for five years.
The re-appointment of an existing director and appointment of a new director, along with the appointment of statutory auditors, are significant corporate governance events that impact the company's leadership and financial oversight.
The company has successfully completed its AGM with key appointments and re-appointments of directors and auditors, ensuring continuity and compliance.
Dr. Reddy's Laboratories Limited announced that its members, at the 42nd Annual General Meeting (AGM) held on July 23, 2026, approved several key resolutions.
Dr. K P Krishnan has been re-appointed as an Independent Director for a second term of five consecutive years, effective from January 7, 2027, to January 6, 2032. He is not related to any Directors or Key Managerial Personnel and is not debarred from holding a Director's office.
Additionally, Mr. Srikanth Velamakanni has been appointed as an Independent Director for a term of five consecutive years, from July 1, 2026, to June 30, 2031. He also has no affiliations with current Directors or KMPs and meets the legal criteria for the role.
The company also approved the appointment of M/s Deloitte Haskins & Sells, LLP, Chartered Accountants, as the Statutory Auditors. This appointment is for a term of five consecutive years, commencing from the conclusion of the 42nd AGM until the conclusion of the 47th AGM.
What to do with a filing like this
Dr. Reddy's Laboratories Limited filed this with the NSE as a statutory disclosure, categorised under board changes. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Dr. Reddy's Laboratories Limited. Read the original for the full detail.